Stifel Nicolaus Initiates Coverage on Avalo Therapeutics (NASDAQ:AVTX)

Research analysts at Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $36.00 price target on the stock. Stifel Nicolaus’ target price suggests a potential upside of 371.82% from the company’s previous close.

Several other equities analysts have also recently issued reports on AVTX. BTIG Research started coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler started coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Stock Performance

Shares of NASDAQ:AVTX opened at $7.63 on Tuesday. The stock’s 50-day moving average is $7.47 and its 200 day moving average is $9.13. Avalo Therapeutics has a 1 year low of $4.60 and a 1 year high of $34.46.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. BVF Inc. IL grew its holdings in Avalo Therapeutics by 7.2% in the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock worth $7,703,000 after purchasing an additional 69,679 shares during the period. Ikarian Capital LLC boosted its position in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after purchasing an additional 915,629 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics in the 3rd quarter worth approximately $9,186,000. Affinity Asset Advisors LLC increased its position in Avalo Therapeutics by 1,123.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after buying an additional 505,765 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in Avalo Therapeutics during the fourth quarter valued at $817,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.